Reuters logo
BRIEF-Bristol-Myers Squibb, Cytomx Therapeutics extend worldwide collaboration
March 20, 2017 / 11:29 AM / 8 months ago

BRIEF-Bristol-Myers Squibb, Cytomx Therapeutics extend worldwide collaboration

March 20 (Reuters) - Bristol-myers Squibb Co:

* Bristol-Myers Squibb and Cytomx Therapeutics extend worldwide collaboration to discover Probody Therapeutics for the treatment of cancer and other diseases

* Bristol-Myers Squibb Co - Cytomx to receive $200 million upfront payment

* Bristol-Myers Squibb - Cytomx will also be eligible to receive up to $448 million in future development, regulatory,sales milestone payments for each collaboration target

* Bristol-Myers Squibb Co - collaboration includes up to eight additional targets in oncology and other therapeutic areas

* Bristol-Myers Squibb Co - Cytomx will grant Bristol-Myers Squibb exclusive worldwide rights to develop and commercialize Probody Therapeutics Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below